Posted by Michael Wonder on 11 Apr 2023
RegenxBio receives FDA fast track designation for RGX-202, a novel gene therapy candidate for the treatment of Duchenne muscular dystrophy
11 April 2023 - RGX-202 is a potential one-time AAV therapeutic for the treatment of Duchenne and includes an optimised transgene for a novel microdystrophin and RegenxBio's proprietary NAV AAV8 vector.
RegenxBio today announced that the US FDA has granted fast track designation for RGX-202, a potential one-time gene therapy for the treatment of Duchenne muscular dystrophy.
